Cargando…

109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy

BACKGROUND: The Accelerate Pheno(TM) system yields identification (ID) and antimicrobial susceptibility testing (AST) within 7 hours of growth in blood culture. The objective of this study was to determine its impact on time to de-escalation of antimicrobial therapy. METHODS: This retrospective quas...

Descripción completa

Detalles Bibliográficos
Autores principales: Powers, Caroline, Moenster, Ryan P, Linneman, Travis W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776919/
http://dx.doi.org/10.1093/ofid/ofaa439.154
_version_ 1783630792038023168
author Powers, Caroline
Moenster, Ryan P
Linneman, Travis W
author_facet Powers, Caroline
Moenster, Ryan P
Linneman, Travis W
author_sort Powers, Caroline
collection PubMed
description BACKGROUND: The Accelerate Pheno(TM) system yields identification (ID) and antimicrobial susceptibility testing (AST) within 7 hours of growth in blood culture. The objective of this study was to determine its impact on time to de-escalation of antimicrobial therapy. METHODS: This retrospective quasi-experimental, observational cohort study included patients hospitalized at the St. Louis VA who received intravenous antibiotics for a positive blood culture. Patients with blood cultures positive for polymicrobial growth or fungi or those requiring antibiotics for other infections were excluded. The primary endpoint was time to de-escalation of antimicrobial therapy from before and after implementation of Accelerate Pheno(TM) (September 2017 to August 2018 and September 2018 to August 2019, respectively). Secondary outcomes included time to ID and AST, length of hospital stay, and days of antimicrobial therapy. The variables of gram-positive infections, use of Accelerate Pheno(TM), and presence of infectious diseases consult and/or pharmacist antimicrobial stewardship note were included in a univariate analysis. Variables with a p-value< 0.2 were included in a multivariate regression. RESULTS: 168 patients were included, with 92 patients in the pre-implementation and 76 in the post-implementation group. Overall, mean age was 67 years and 162 (96%) were men. Staphylococcus spp. and Escherichia coli were the most common causative organisms. Time to de-escalation did not differ significantly between the post-implementation and pre-implementation groups (65 vs. 61 hours, p=0.47). Time to organism ID was decreased by 16 hours using Accelerate Pheno(TM) (50 vs. 66 hours, p=0.016). However, no difference was found in time to AST or length of hospital stay. Days of antimicrobial therapy while hospitalized was also similar between groups (6.8 vs. 5.9 days, p=0.256). Only gram-positive infections and presence of antimicrobial stewardship notes were included in the multivariate regression. Neither were independently associated with de-escalation within 48 hours. CONCLUSION: Accelerate Pheno(TM) system did not impact time to de-escalation of antimicrobial therapy. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77769192021-01-07 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy Powers, Caroline Moenster, Ryan P Linneman, Travis W Open Forum Infect Dis Poster Abstracts BACKGROUND: The Accelerate Pheno(TM) system yields identification (ID) and antimicrobial susceptibility testing (AST) within 7 hours of growth in blood culture. The objective of this study was to determine its impact on time to de-escalation of antimicrobial therapy. METHODS: This retrospective quasi-experimental, observational cohort study included patients hospitalized at the St. Louis VA who received intravenous antibiotics for a positive blood culture. Patients with blood cultures positive for polymicrobial growth or fungi or those requiring antibiotics for other infections were excluded. The primary endpoint was time to de-escalation of antimicrobial therapy from before and after implementation of Accelerate Pheno(TM) (September 2017 to August 2018 and September 2018 to August 2019, respectively). Secondary outcomes included time to ID and AST, length of hospital stay, and days of antimicrobial therapy. The variables of gram-positive infections, use of Accelerate Pheno(TM), and presence of infectious diseases consult and/or pharmacist antimicrobial stewardship note were included in a univariate analysis. Variables with a p-value< 0.2 were included in a multivariate regression. RESULTS: 168 patients were included, with 92 patients in the pre-implementation and 76 in the post-implementation group. Overall, mean age was 67 years and 162 (96%) were men. Staphylococcus spp. and Escherichia coli were the most common causative organisms. Time to de-escalation did not differ significantly between the post-implementation and pre-implementation groups (65 vs. 61 hours, p=0.47). Time to organism ID was decreased by 16 hours using Accelerate Pheno(TM) (50 vs. 66 hours, p=0.016). However, no difference was found in time to AST or length of hospital stay. Days of antimicrobial therapy while hospitalized was also similar between groups (6.8 vs. 5.9 days, p=0.256). Only gram-positive infections and presence of antimicrobial stewardship notes were included in the multivariate regression. Neither were independently associated with de-escalation within 48 hours. CONCLUSION: Accelerate Pheno(TM) system did not impact time to de-escalation of antimicrobial therapy. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776919/ http://dx.doi.org/10.1093/ofid/ofaa439.154 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Powers, Caroline
Moenster, Ryan P
Linneman, Travis W
109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title_full 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title_fullStr 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title_full_unstemmed 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title_short 109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
title_sort 109. impact of accelerate pheno(tm) system on time to de-escalation of antimicrobial therapy
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776919/
http://dx.doi.org/10.1093/ofid/ofaa439.154
work_keys_str_mv AT powerscaroline 109impactofacceleratephenotmsystemontimetodeescalationofantimicrobialtherapy
AT moensterryanp 109impactofacceleratephenotmsystemontimetodeescalationofantimicrobialtherapy
AT linnemantravisw 109impactofacceleratephenotmsystemontimetodeescalationofantimicrobialtherapy